JP5209166B2 - ポルフィロモナス・ジンジバリス(Porphyromonasgingivalis)リコンビナントタンパク質と末端切断物 - Google Patents
ポルフィロモナス・ジンジバリス(Porphyromonasgingivalis)リコンビナントタンパク質と末端切断物 Download PDFInfo
- Publication number
- JP5209166B2 JP5209166B2 JP2001580954A JP2001580954A JP5209166B2 JP 5209166 B2 JP5209166 B2 JP 5209166B2 JP 2001580954 A JP2001580954 A JP 2001580954A JP 2001580954 A JP2001580954 A JP 2001580954A JP 5209166 B2 JP5209166 B2 JP 5209166B2
- Authority
- JP
- Japan
- Prior art keywords
- gingivalis
- polypeptide
- antibody
- soluble
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241000605862 Porphyromonas gingivalis Species 0.000 title claims description 68
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 title description 29
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 title description 29
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 73
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 73
- 229920001184 polypeptide Polymers 0.000 claims description 71
- 239000012634 fragment Substances 0.000 claims description 59
- 239000000203 mixture Substances 0.000 claims description 44
- 238000000034 method Methods 0.000 claims description 22
- 108020004414 DNA Proteins 0.000 claims description 20
- 239000013604 expression vector Substances 0.000 claims description 12
- 230000028993 immune response Effects 0.000 claims description 9
- 208000015181 infectious disease Diseases 0.000 claims description 9
- 102000053602 DNA Human genes 0.000 claims description 8
- 239000002671 adjuvant Substances 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- 238000003259 recombinant expression Methods 0.000 claims description 6
- 108700029229 Transcriptional Regulatory Elements Proteins 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 101001086534 Porphyromonas gingivalis (strain ATCC BAA-308 / W83) Outer membrane protein 41 Proteins 0.000 description 48
- 210000004027 cell Anatomy 0.000 description 44
- 108090000623 proteins and genes Proteins 0.000 description 38
- 101000992168 Porphyromonas gingivalis (strain ATCC BAA-308 / W83) Outer membrane protein 40 Proteins 0.000 description 32
- 102000004169 proteins and genes Human genes 0.000 description 27
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 26
- 235000018102 proteins Nutrition 0.000 description 25
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 23
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 23
- 150000001413 amino acids Chemical class 0.000 description 19
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 15
- 241000588724 Escherichia coli Species 0.000 description 14
- 102000037865 fusion proteins Human genes 0.000 description 14
- 108020001507 fusion proteins Proteins 0.000 description 14
- 239000004202 carbamide Substances 0.000 description 13
- 238000005119 centrifugation Methods 0.000 description 13
- 239000000551 dentifrice Substances 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- -1 adhesion factors Substances 0.000 description 12
- 208000028169 periodontal disease Diseases 0.000 description 12
- 235000001014 amino acid Nutrition 0.000 description 11
- 239000000872 buffer Substances 0.000 description 11
- 239000000499 gel Substances 0.000 description 11
- 239000006072 paste Substances 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 239000008188 pellet Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 238000006467 substitution reaction Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 238000001262 western blot Methods 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 230000004927 fusion Effects 0.000 description 8
- 230000003902 lesion Effects 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 235000013336 milk Nutrition 0.000 description 8
- 239000008267 milk Substances 0.000 description 8
- 210000004080 milk Anatomy 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 239000000606 toothpaste Substances 0.000 description 8
- 229940034610 toothpaste Drugs 0.000 description 8
- 229960005486 vaccine Drugs 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000002324 mouth wash Substances 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000003082 abrasive agent Substances 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 229940051866 mouthwash Drugs 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 5
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 5
- 239000006137 Luria-Bertani broth Substances 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 239000012148 binding buffer Substances 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 230000009257 reactivity Effects 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000000600 sorbitol Substances 0.000 description 5
- 235000010356 sorbitol Nutrition 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 4
- 241000335876 Porphyromonas gingivalis W50 Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 229960001212 bacterial vaccine Drugs 0.000 description 4
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 210000000214 mouth Anatomy 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 239000013615 primer Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000000527 sonication Methods 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 3
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 239000003155 DNA primer Substances 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000672609 Escherichia coli BL21 Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 208000005888 Periodontal Pocket Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 229940112822 chewing gum Drugs 0.000 description 3
- 235000015218 chewing gum Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000008119 colloidal silica Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000007859 condensation product Substances 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 210000003000 inclusion body Anatomy 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
- 229930027917 kanamycin Natural products 0.000 description 3
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 3
- 229960000318 kanamycin Drugs 0.000 description 3
- 229930182823 kanamycin A Natural products 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 125000005341 metaphosphate group Chemical group 0.000 description 3
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 238000005185 salting out Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- AQMNWCRSESPIJM-UHFFFAOYSA-M sodium metaphosphate Chemical compound [Na+].[O-]P(=O)=O AQMNWCRSESPIJM-UHFFFAOYSA-M 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 210000005253 yeast cell Anatomy 0.000 description 3
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 2
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 2
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 108700010070 Codon Usage Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- XVOYSCVBGLVSOL-UHFFFAOYSA-N cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 229940025294 hemin Drugs 0.000 description 2
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 229940094522 laponite Drugs 0.000 description 2
- XCOBTUNSZUJCDH-UHFFFAOYSA-B lithium magnesium sodium silicate Chemical compound [Li+].[Li+].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3 XCOBTUNSZUJCDH-UHFFFAOYSA-B 0.000 description 2
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 1
- MRTPISKDZDHEQI-YFKPBYRVSA-N (2s)-2-(tert-butylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC(C)(C)C MRTPISKDZDHEQI-YFKPBYRVSA-N 0.000 description 1
- NPDBDJFLKKQMCM-SCSAIBSYSA-N (2s)-2-amino-3,3-dimethylbutanoic acid Chemical compound CC(C)(C)[C@H](N)C(O)=O NPDBDJFLKKQMCM-SCSAIBSYSA-N 0.000 description 1
- JLPAMKUIIFHLBH-UHFFFAOYSA-N 1,2-dihydroxypropane-1-sulfonic acid Chemical compound CC(O)C(O)S(O)(=O)=O JLPAMKUIIFHLBH-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- RPZANUYHRMRTTE-UHFFFAOYSA-N 2,3,4-trimethoxy-6-(methoxymethyl)-5-[3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxyoxane;1-[[3,4,5-tris(2-hydroxybutoxy)-6-[4,5,6-tris(2-hydroxybutoxy)-2-(2-hydroxybutoxymethyl)oxan-3-yl]oxyoxan-2-yl]methoxy]butan-2-ol Chemical compound COC1C(OC)C(OC)C(COC)OC1OC1C(OC)C(OC)C(OC)OC1COC.CCC(O)COC1C(OCC(O)CC)C(OCC(O)CC)C(COCC(O)CC)OC1OC1C(OCC(O)CC)C(OCC(O)CC)C(OCC(O)CC)OC1COCC(O)CC RPZANUYHRMRTTE-UHFFFAOYSA-N 0.000 description 1
- OGNSCSPNOLGXSM-UHFFFAOYSA-N 2,4-diaminobutyric acid Chemical compound NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- FMYBFLOWKQRBST-UHFFFAOYSA-N 2-[bis(carboxymethyl)amino]acetic acid;nickel Chemical compound [Ni].OC(=O)CN(CC(O)=O)CC(O)=O FMYBFLOWKQRBST-UHFFFAOYSA-N 0.000 description 1
- LFJJOPDNPVFCNZ-UHFFFAOYSA-N 2-[hexadecanoyl(methyl)amino]acetic acid Chemical class CCCCCCCCCCCCCCCC(=O)N(C)CC(O)=O LFJJOPDNPVFCNZ-UHFFFAOYSA-N 0.000 description 1
- NGOZDSMNMIRDFP-UHFFFAOYSA-N 2-[methyl(tetradecanoyl)amino]acetic acid Chemical class CCCCCCCCCCCCCC(=O)N(C)CC(O)=O NGOZDSMNMIRDFP-UHFFFAOYSA-N 0.000 description 1
- AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 239000005696 Diammonium phosphate Substances 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 240000000896 Dyera costulata Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 244000004281 Eucalyptus maculata Species 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 240000001238 Gaultheria procumbens Species 0.000 description 1
- 235000007297 Gaultheria procumbens Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- XIGSAGMEBXLVJJ-YFKPBYRVSA-N L-homocitrulline Chemical compound NC(=O)NCCCC[C@H]([NH3+])C([O-])=O XIGSAGMEBXLVJJ-YFKPBYRVSA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 101710164702 Major outer membrane protein Proteins 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229920000877 Melamine resin Polymers 0.000 description 1
- 244000024873 Mentha crispa Species 0.000 description 1
- 235000014749 Mentha crispa Nutrition 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 101000723939 Mus musculus Transcription factor HIVEP3 Proteins 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 244000227633 Ocotea pretiosa Species 0.000 description 1
- 235000004263 Ocotea pretiosa Nutrition 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 235000011203 Origanum Nutrition 0.000 description 1
- 240000000783 Origanum majorana Species 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- XCOJIVIDDFTHGB-UEUZTHOGSA-N Perillartine Chemical compound CC(=C)[C@H]1CCC(\C=N\O)=CC1 XCOJIVIDDFTHGB-UEUZTHOGSA-N 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 229920001807 Urea-formaldehyde Polymers 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 229920006387 Vinylite Polymers 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000008431 aliphatic amides Chemical class 0.000 description 1
- 229910052910 alkali metal silicate Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 229940072049 amyl acetate Drugs 0.000 description 1
- PGMYKACGEOXYJE-UHFFFAOYSA-N anhydrous amyl acetate Natural products CCCCCOC(C)=O PGMYKACGEOXYJE-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 238000005574 benzylation reaction Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 1
- 229940043256 calcium pyrophosphate Drugs 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical class C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 239000011538 cleaning material Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 229910002026 crystalline silica Inorganic materials 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- 229910000388 diammonium phosphate Inorganic materials 0.000 description 1
- 235000019838 diammonium phosphate Nutrition 0.000 description 1
- 235000019821 dicalcium diphosphate Nutrition 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- IVJISJACKSSFGE-UHFFFAOYSA-N formaldehyde;1,3,5-triazine-2,4,6-triamine Chemical compound O=C.NC1=NC(N)=NC(N)=N1 IVJISJACKSSFGE-UHFFFAOYSA-N 0.000 description 1
- SLGWESQGEUXWJQ-UHFFFAOYSA-N formaldehyde;phenol Chemical compound O=C.OC1=CC=CC=C1 SLGWESQGEUXWJQ-UHFFFAOYSA-N 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- 229940051250 hexylene glycol Drugs 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910000400 magnesium phosphate tribasic Inorganic materials 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 210000002379 periodontal ligament Anatomy 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229920001568 phenolic resin Polymers 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- ODGAOXROABLFNM-UHFFFAOYSA-N polynoxylin Chemical compound O=C.NC(N)=O ODGAOXROABLFNM-UHFFFAOYSA-N 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- OQZCJRJRGMMSGK-UHFFFAOYSA-M potassium metaphosphate Chemical compound [K+].[O-]P(=O)=O OQZCJRJRGMMSGK-UHFFFAOYSA-M 0.000 description 1
- 229940099402 potassium metaphosphate Drugs 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229940021993 prophylactic vaccine Drugs 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 108700004121 sarkosyl Proteins 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 229960001462 sodium cyclamate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- UGTZMIPZNRIWHX-UHFFFAOYSA-K sodium trimetaphosphate Chemical compound [Na+].[Na+].[Na+].[O-]P1(=O)OP([O-])(=O)OP([O-])(=O)O1 UGTZMIPZNRIWHX-UHFFFAOYSA-K 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 229920001187 thermosetting polymer Polymers 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000012178 vegetable wax Substances 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000007222 ypd medium Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- GFQYVLUOOAAOGM-UHFFFAOYSA-N zirconium(iv) silicate Chemical compound [Zr+4].[O-][Si]([O-])([O-])[O-] GFQYVLUOOAAOGM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/806—Antigenic peptides or proteins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/825—Bacteria
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Cosmetics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
本発明はポルフィロモナス・ジンジバリス(Porphyromonas gingivalis)のヌクレオチド配列およびP. gingivalisのポリペプチドに関する。P. gingivalisのポリペプチドおよびヌクレオチドは、被験者のP. gingivalisに対して免疫応答を起こすのにならびに歯周病として知られる症状またはP. gingivalisによる感染に関係する他の症状の重篤度を治療または予防または軽減するのに使用する組成物において使用することができる。
歯周病は細菌に関連する歯の支持組織の炎症疾患であり、比較的穏やかな形態の歯肉炎である非特定的かつ可逆的な歯肉組織の炎症から、歯支持構造の破壊により特徴づけられるもっと攻撃的な形態の歯周病まである。歯周病は歯根膜の破壊に導く特定のグラム陰性菌のコンソーシアムの歯肉下感染に関連し、重要な公衆衛生問題である。大きな関心を呼んでいる1つの細菌はP. gingivalisであり、その理由は、この微生物の成人歯周病病変部からの回収は歯肉下の嫌気性培養可能なフローラの50%にまで達しうるが、P. gingivalisは健康部位からは稀にしかも少数しか回収されないからである。歯肉下プラーク中のP. gingivalisレベルは歯周病の重症度の増加に関連して比例的に増加し、この疾患が回復すると培養可能な歯肉下微生物集団からの該微生物は根絶される。P.gingivalisの歯肉下移植による、非ヒト霊長類の歯周病病変の進行が実証されている。動物およびヒトの両方に対するこれらの知見は、成人の歯周病発達におけるP.gingivalisの重要な役割を示唆する。
本発明者らはこのほど、全長タンパク質と比較すると溶解度の改善を示すP. gingivalisのPG32およびPG33タンパク質の断片を同定した。マウスの感染病変モデルを使って、本発明者らはこれらの可溶性断片がP. gingivalisのチャレンジに対する保護能があることを発見した。
[式中、
Yは、配列番号3の残基86〜223、配列番号3の残基191〜322、配列番号4の残基193〜310、配列番号3の残基191〜306、配列番号3の残基224〜391、配列番号4の残基213〜380、配列番号4の残基286〜380、配列番号3の残基224〜306、配列番号4の残基213〜285、配列番号3の残基281〜384および配列番号4の残基306〜372からなる群から選択されるアミノ酸配列からなる可溶性P. gingivalisの断片であり;そして
XとZは、存在するかまたは存在せず、かつP. gingivalisの断片の溶解度に実質的に悪影響を与えないアミノ酸もしくはペプチドからなる]
で表される可溶性ポリペプチドを提供する。
口腔内細菌ポルフィロモナス・ジンジバリス(Porphyromonas gingivalis)はその表面上に主要外膜タンパク質PG32およびPG33を含有する。これらのタンパク質の末端切断された可溶性断片は、全長タンパク質と比較すると、マウス膿瘍モデルにおいてP. gingivalisチャレンジに対する保護の改善を提供する。
[式中、
Yは、配列番号3の残基86〜223、配列番号3の残基191〜322、配列番号4の残基193〜310、配列番号3の残基191〜306、配列番号3の残基224〜391、配列番号4の残基213〜380、配列番号4の残基286〜380、配列番号3の残基224〜306、配列番号4の残基213〜285、配列番号3の残基281〜384および配列番号4の残基306〜372からなる群から選択されるアミノ酸配列からなる可溶性P. gingivalis断片であり;そして
XとZは、存在するかまたは存在せず、かつP. gingivalis断片の溶解度に実質的に悪影響を与えないアミノ酸もしくはペプチドからなる]
で表されるポリペプチドも提供する。
実施例1:P. gingivalisリコンビナントタンパク質PG32およびPG33ならびにこれらのタンパク質の断片または末端切断物(truncation)のクローニングと分析
(a) P. gingivalis末端切断タンパク質のクローニング
PG32(GenBank登録番号AF175714)およびP33(GenBank登録番号AF175715)は、P.gingivalis株W50の免疫反応性タンパク質としてすでに説明されている。その完全なDNA配列とタンパク質配列は、PG32についてはそれぞれ配列番号1と3に、またPG33についてはそれぞれ配列番号2と4に与えられている。
単一コロニー形質転換体を用いて、50 μg/mlカナマイシンを含有するLuria-Bertaniブロス(LB)20mlに接種して、37℃で一夜振とうした。次いでこの接種菌を用いて、テリフィック(Terrific)ブロス500ml(リン酸カリウムおよび50μg/mlカナマイシンを含有する)に接種して、37℃で吸光度(OD600)が2.0になるまで振とうした。培養物を0.1mM IPTGを用いて誘導した。30℃または37℃で1〜4時間の誘導期間後に培養物を、4℃で4000rpmにて10分間遠心分離することによって回収して、ペレットを-70℃で保存してリコンビナントタンパク質の溶解度測定に備えた。
IPTG誘導後に、r-PG32またはr-PG33タンパク質あるいはそれらの末端切断物の発現レベルと溶解度を評価した。約14mlのリコンビナント大腸菌(E.coli)細胞培養物を遠心分離によりペレット化し、そして、TE pH8.0の1.5mlに再懸濁した。次に細胞を5設定でマイクロプローブ(Virosonic Digital 475 超音波細胞破砕機、The Virtis社、NY)を使って2 X 10秒間のバーストで超音波処理した。15分間の遠心分離(13,000rpm)後に上清を回収して、これを可溶性画分とした。ペレットを洗浄し、次にTE pH8.0に再懸濁して、これを不溶性画分とした。様々な画分の分析をウェスタンブロット分析とSDS-PAGEを用いて実施した。これらの実験結果を表3に示す。複数の事例では、NOGおよびCHAPSなどの非イオン性洗剤を0.1〜1%で超音波処理プロセスに加えて、リコンビナントタンパク質の可溶化を助けた。大規模な発現および精製の目的のために、大腸菌(E.coli)培養物500mlを遠心分離によりペレット化して、1x結合バッファー(5 mMイミダゾール、500nM NaCl、 20mM Tris-HCl、 pH 7.9)40mlに再懸濁した。次いで細胞を、8の設定のマイクロプローブ(0.5")(Virosonic Digital 475超音波細胞破砕機、The Virtis社、NY)を使って、6 X 10秒バーストで超音波処理した。15分間の遠心分離(13,000rpm)後に、可溶性リコンビナントタンパク質を含有する上清を回収して、以下に概説したように精製した。
全長PG32(配列番号3;残基21-391)およびPG33(配列番号4;残基22-380)の事例のようにr-タンパク質が不溶性であるとわかると、リコンビナント大腸菌(E.coli)ペレットを氷上で解凍して結合バッファーに再懸濁し、次いで超音波処理し、20,000 x gで遠心分離して封入体を回収した。ペレットを結合バッファーに再懸濁し、超音波処理と遠心分離のプロセスを2回以上繰返してさらにタンパク質を遊離させた。次いでペレットを6M尿素を含有する結合バッファーに再懸濁し、氷上で2〜3時間攪拌しながらインキュベートして完全にタンパク質を溶解した。39,000 x g、20分間の遠心分離によって残留する不溶性物質を除去した。上清は、カラム精製の前に0.45μm膜を通して濾過した。
Ni-NTA金属アフィニティクロマトグラフィを使ってリコンビナントタンパク質をH6タグを介して精製した。簡単に説明すると、タンパク質を平衡化Ni-NTA樹脂(Qiagen)にバッチ結合させて、これを小カラム中に注いで重力下で未結合タンパク質を溶出した。次にカラムを結合バッファー10mlを用いて洗浄し、次いで洗浄バッファー(60 mMイミダゾール、500mM NaCl、20mM Tris-HCI、pH7.9)6mlによって洗浄した。次に結合したタンパク質を、1Mイミダゾール、500mM NaCl、20mM Tris-HCI、pH 7.9を含有するバッファー中に溶出した。可溶化封入体または不溶性リコンビナントタンパク質を精製する場合には、上記バッファーに6M尿素を加えた。
尿素を含有しない調製物については、Ni-NTA樹脂からの溶出タンパク質画分をプールした後、痕跡量のイミダゾールを除去するために0.5M Tris-HCl、50mM NaClに対する透析を行った。
SDS-PAGEは本質的にNovexによる推奨の通り実施した。サンプルを2 x サンプル還元バッファー(Novex)の等容積と混合し、100℃で10分間ボイルし、Tris-グリシン4〜20%ゲル(Novex)に適用した。分子量標準(SeeBlueTM)もNovexから購入した。ウェスタンブロットは、電気泳動後に、タンパク質をニトロセルロース上に1時間100ボルトでエレクトロブロッティングして調製した。メンブランを5%のスキムミルク-PBSを用いてブロッキングした後、1/5000に希釈した抗ウサギ抗体と共に、または5%のスキムミルク-PBS中に1/1000に希釈した抗ラット抗体と共にインキュベートした。メンブランをその後洗浄し、ヤギ抗ウサギ-HRPコンジュゲート(KPL)またはヤギ抗マウス-HRPコンジュゲート(KPL)と共にインキュベートし、洗浄し、そしてTMBメンブランペルオキシダーゼ基質(KPL)を用いて顕色した。
BALB/cマウスに、PG32(構築物21)組換えタンパク質20μgを含むフロイント不完全アジュバント(FIA;Sigma)を2回、3週間隔で投与することによって、精製組換えタンパク質に対するポリクローナル抗血清を産生させた。2回目の投与の1週間後にマウスから採血し、産生された抗血清を用いて、変性および還元条件下で泳動したP. gingivalis W50の全体細胞のウェスタンブロットをスクリーニングした。また、ウサギにおいても、P. gingivalis全体細胞(W50株)またはP. gingivalis細胞(W50株)のサルコシル不溶性濃縮画分(グラム陰性生物の外側膜タンパク質を濃縮する方法により)を含むFIAを、3回投与して免疫感作して、抗血清を産生させた。また、ラットにおいても、P. gingivalis W50の全体細胞を含むフロイント不完全アジュバントを用いて免疫感作して、抗血清を産生させた。次いでラットにP. gingivalis生細胞(ATCC 33277株)を経口投与してチャレンジし、6週後に採血した。これらのラットは、対照ラットと比較して、チャレンジ後の大臼歯周囲の歯槽骨の損失から守られていることを示した。
10匹の雌のBALB/cマウス(6-8週齢)からなる群を、各組換えタンパク質、PG32(0.5M尿素中に含まれる構築物1)、PG33(2M尿素中に含まれる構築物2)、PG32断片(構築物21)およびPG33断片(構築物22)を用いて、皮下へ免疫感作した(20μg/投与量)。対照マウスにはホルマリン殺菌P. gingivalis細胞(ほぼ2×109)、または大腸菌(E.coli)ライセート(20pg/投与)を、いずれも不完全フロイントアジュバント(Sigma)中に乳化して与えた。この免疫感作は、尾の基部に皮下注射して与え、P. gingivalisによるチャレンジの4週前および1週前に実施した。チャレンジの2日前に、マウスの球後神経叢(retrobulbar plexus)から採血した。BALB/cマウスにP. gingivalis 33277の7.5 x 109生細胞を腹部の腹側領域中に皮下注射してチャレンジした。チャレンジ後、7日間にわたって毎日、病変の数とサイズについてマウスを試験した。病変が注射部位周囲のマウス腹部に発生したのでその病変を毎日測定した。
PG32断片(aa224-391)のクローニング。 PG32(構築物21)を、実施例1に概説したようにして、PCR増幅して抽出した。精製したDNAは、先にEcoRIおよびNotIを用いて消化しておいた、QIAexII精製した酵母GST発現ベクターpYEX4T-1(Amrad)中にライゲートした。ライゲーション産物をカルシウムコンピテント大腸菌(E.coli)BL21 DE3 (Stratagene)中に形質転換し、50μgアンピシリンを含有するLBプレート上で選択した。組換えプラスミドを含有する大腸菌(E.coli)細胞の単一コロニーをアンピシリンを含有するテリフィック(Terrific)ブロスを含む100ml培養中に接種して一夜培養し、そしてそのプラスミドを、酵母中に形質転換する前に、QIAGEN Plasmid Maxiキットを用いて精製した。
S.セレビシエ(S. cerevisiae)DY150グリセロールストックのサンプルをYPDプレート上にストリークして、30℃で3〜4日間放置した。単一コロニーを20ml YPD培地中に接種して、30℃にて24時間振とうした。500μl容量の一夜培養物を3000rpmにて5分間、遠心分離にかけ、そのDY150ペレットを1mlのdH20で洗浄した。ペレットを10mg/ml子ウシ胸腺DNA(Sigma)に再懸濁し、それに1μgのプラスミドDNAをプレート溶液の500μlとともに加えて、その混合物を25℃にて24時間インキュベートした。細胞を3000rpmにて5分間、遠心沈降して、プレート溶液を除去した。酵母を1mlのdH20で洗浄し、YNBSプレート上にプレーティングして30℃にて4〜5日間インキュベートした。
単一コロニー形質転換体を5mlのYNBSブロスに接種し、30℃にて48時間振とうした。0.5mlの種苗を5mlの新鮮なYNBSブロスに加え、0.5mM CuS04を用いて誘導を行った。30℃にて3時間の誘導期間後に、培養物を遠心分離によって回収し、500μlブレーキングバッファー(1mM PMSFおよび10mM E-64を含有、Sigma)に再懸濁した。2.0mlスクリュー栓バイアル(Biospec)を、3/4量は0.5mmガラスビーズ(Biospec)によって満たし、残りの容積は細胞によって満たした。その混合物を、ミニ・ビーズビーター細胞破砕機(Biospec)中で30秒(5,000rpm)×8回ホモジナイズし、その各作動の間は、氷上で30秒インキュベーションした。ビーズを静置沈降させて、破砕された酵母細胞を回収した。5分間の遠心分離(3000g)の後、上清を回収し、これを可溶性画分とした。ペレットはブレーキングバッファー中に再懸濁して不溶性画分とした。画分はSDS-PAGEとウェスタンブロット分析を用いて分析した。
合成PG32末端切断型遺伝子(PG32 aa224-391に対応)を、S.セレビシエ(S. cerevisiae)の推定上のコドン使用を利用して構築し、S.セレビシエ中のP. gingivalisタンパク質の発現を改善した。表4に掲げた2本鎖DNA配列全体をカバーするオリゴヌクレオチドを、酵母中の発現用に高発現バイアスコドンを用いて設計した(Sharp,P.MおよびCowe,E.(1991)Yeast. 7, 657-678)。オリゴヌクレオチドプライマーAおよびBを、 TaqPlus precision (Stratagene) DNAポリメラーゼを使って、次の条件下でのPCRにより、dsDNA断片に変換した:変性(96℃、1分間)、アニーリング(53℃、1分間)および伸長(72℃、2分間)の20サイクルとし、かつ伸長ステップの継続時間をサイクル毎に5秒ずつ増加する(Di Donato,A., de Nigris,M., Russo,N., Di Biase,S.およびD'Alessio, G. (1993) Analytical Biochemistry. 212, 291-293)。第2のPCRランでは、コア混合物の1/20アリコートを、コアテンプレート延長に機能するオリゴヌクレオチドプライマーCおよびDと共に使用した。この操作を各プライマー対を使用して繰返し、最終的に500bp産物を作製した。このPCR産物をプロテイナーゼK (Boehringer Mannheim)処理し、QIAquick PCR精製キット(Qiagen)を用いて精製し、プライマーにより導入された制限酵素切断部位EcoRIおよびNotIで消化した。DNA断片を、1%低融点アガロースゲル(Bio-Rad)を通す電気泳動によって精製し、QIAexIIゲル抽出キット(Qiagen)を使って抽出した。精製したDNAを、先にEcoRIおよびNotIを用いて消化しておいたQIAexII精製済の酵母GST発現ベクターpYEX4T1(Amrad)中にライゲートした。ライゲーション産物をカルシウムコンピテント大腸菌(E.coli)BL21 DE3(Stratagene)中に形質転換して、50μgアンピシリンを含有するLBプレート上で選択した。コドンを置き換えたインサートが正確であることをDNA配列分析によって確認した。酵母の形質転換とPG32の発現を前に概説した通り実施した。図2は、酵母により発現された、GSTと融合した合成PG32(aa224-391)の発現および免疫反応性を示す。図2aおよび2bにおいて、レーン3は、酵母により発現された未改変P. gingivalisコドンを含有し、レーン4、5、6、7は、それらのコドンを以上概説したようにして酵母での発現に対して最適化したクローンを含有する。特にPG32に対する抗血清を用いたとき(図2b)の、ほぼ48kD(矢印を参照)のバンドにおける反応性増加によって立証されるように、コドン最適化が行われると、ある程度の発現と免疫反応性の増加があるようである。
Claims (18)
- P. gingivalisに対する免疫応答を起こすことができる、配列番号3の残基86〜223、配列番号3の残基191〜322、配列番号3の残基224〜391、配列番号4の残基213〜380、配列番号3の残基224〜306、および配列番号3の残基281〜384からなる群から選択される配列を有するポリペプチドからなる、可溶性P. gingivalisのポリペプチド。
- 請求項1に記載の可溶性ポリペプチドを含んでなるキメラ構築物。
- 請求項1に記載の可溶性ポリペプチドをコードするヌクレオチド配列を含んでなる単離されたDNA分子。
- 転写調節エレメントと機能的に連結された請求項3に記載のDNA分子を含んでなるリコンビナント発現ベクター。
- 請求項4に記載のリコンビナント発現ベクターを含んでなる細胞。
- P. gingivalisのポリペプチドを産生する方法であって、該ポリペプチドの発現を可能にする条件下で請求項5に記載の細胞を培養することを含んでなる方法。
- 被験体のP. gingivalisに対する免疫応答を起こすのに使用する組成物であって、請求項1に記載の少なくとも1つの有効量の可溶性ポリペプチド、および/または請求項3に記載の少なくとも1つの有効量のDNA分子、ならびに製薬上許容される担体を含んでなる前記組成物。
- 製薬上許容される担体がアジュバントである、請求項7に記載の組成物。
- 被験体のP. gingivalis感染の発症または重篤度を低減または予防することに使用するための請求項7または8に記載の組成物。
- 請求項1に記載の可溶性ポリペプチドに対して産生され、かつ該可溶性ポリペプチドに対する抗体。
- モノクローナル抗体である、請求項10に記載の抗体。
- ポリクローナル抗体である、請求項10に記載の抗体。
- 請求項10〜12のいずれか1項に記載の抗体および製薬上許容される担体を含んでなる組成物。
- 被験体のP. gingivalis感染を治療または予防することに使用するための請求項10〜12のいずれか1項に記載の抗体または請求項13に記載の組成物。
- 個体に由来するサンプル中のP. gingivalisのポリペプチドの存在または不存在を検出する方法であって、サンプルを請求項10〜12のいずれか1項に記載の抗体と、抗体がサンプル中のP. gingivalisのポリペプチドと免疫複合体を形成するのに十分な条件下で接触させ、そして免疫複合体の存在または不存在を検出することを含んでなる方法。
- 個体に由来するサンプル中のP. gingivalis抗体の存在または不存在を検出する方法であって、サンプルを請求項1に記載の可溶性ポリペプチドまたは請求項2に記載のキメラ構築物と、ポリペプチドの可溶性断片がサンプル中の抗体と免疫複合体を形成するのに十分な条件下で接触させ、そして免疫複合体の存在または不存在を検出することを含んでなる方法。
- 請求項1に記載の可溶性ポリペプチド、または請求項2に記載のキメラ構築物、および/または請求項10〜12のいずれか1項に記載の抗体を含んでなるキット。
- 抗体を産生するための請求項1に記載のポリペプチドの使用であって、該抗体はヒトで産生されない、前記使用。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPQ7182A AUPQ718200A0 (en) | 2000-04-28 | 2000-04-28 | Porphyromonas gingivalis recombinant proteins and truncations |
AU7182 | 2000-04-28 | ||
AUPQ7182 | 2000-04-28 | ||
PCT/AU2001/000482 WO2001083530A1 (en) | 2000-04-28 | 2001-04-27 | Porphyromonas gingivalis recombinant proteins and truncations |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2003531634A JP2003531634A (ja) | 2003-10-28 |
JP2003531634A5 JP2003531634A5 (ja) | 2008-06-05 |
JP5209166B2 true JP5209166B2 (ja) | 2013-06-12 |
Family
ID=3821267
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2001580954A Expired - Fee Related JP5209166B2 (ja) | 2000-04-28 | 2001-04-27 | ポルフィロモナス・ジンジバリス(Porphyromonasgingivalis)リコンビナントタンパク質と末端切断物 |
Country Status (9)
Country | Link |
---|---|
US (1) | US7204991B2 (ja) |
EP (1) | EP1276762B1 (ja) |
JP (1) | JP5209166B2 (ja) |
AU (1) | AUPQ718200A0 (ja) |
CA (2) | CA2750984A1 (ja) |
DK (1) | DK1276762T3 (ja) |
ES (1) | ES2426034T3 (ja) |
NZ (1) | NZ521797A (ja) |
WO (1) | WO2001083530A1 (ja) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPO652897A0 (en) | 1997-04-30 | 1997-05-29 | University Of Melbourne, The | Synthetic peptide constructs for the diagnosis and treatment of periodontitis |
US8129500B2 (en) | 1997-12-10 | 2012-03-06 | Csl Limited | Porphyromonas gingivalis polypeptides and nucleotides |
US7468185B2 (en) | 2001-12-21 | 2008-12-23 | Pfizer Inc. | Vaccine for periodontal disease |
US7378101B2 (en) | 2001-12-21 | 2008-05-27 | Pfizer, Inc. | Vaccine for periodontal disease |
US20060067949A1 (en) * | 2002-11-18 | 2006-03-30 | Genco Caroline A | Immunization with porphyromonas gingivalis protects against heart disease |
WO2006084129A2 (en) * | 2005-02-01 | 2006-08-10 | University Of Florida Research Foundation | Genes of porphyromonas gingivalis w83 involved in invasion of human cells |
US20100092471A1 (en) | 2006-06-27 | 2010-04-15 | Oral Health Australia Pty Ltd | Porphyromonas Gingivalis Polypeptides Useful in the Prevention of Periodontal Disease |
US20100297179A1 (en) * | 2007-07-12 | 2010-11-25 | Stuart Geoffrey Dashper | Immunology Treatment for Biofilms |
CN103357014A (zh) | 2007-07-12 | 2013-10-23 | 口腔健康澳洲私人有限公司 | 生物膜治疗 |
AU2013203250B2 (en) * | 2007-07-12 | 2014-11-13 | Oral Health Australia Pty Ltd | Immunology treatment for biofilms |
US8871213B2 (en) | 2008-08-29 | 2014-10-28 | Oral Health Australia Pty Ltd | Prevention, treatment and diagnosis of P. gingivalis infection |
US8140041B2 (en) * | 2009-08-27 | 2012-03-20 | Mediatek Inc. | Tunable capacitive device with linearization technique employed therein |
US20210308028A1 (en) * | 2020-03-30 | 2021-10-07 | Colgate-Palmolive Company | Compositions and Methods for Maintaining and Protecting Tissue Integrity and Barrier Function |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5536497A (en) * | 1992-12-21 | 1996-07-16 | The Research Foundation Of State University Of New York | Fimbrial polypeptides useful in the prevention of periodontitis |
US5523390A (en) | 1993-09-10 | 1996-06-04 | University Of Georgia Research Foundation, Inc. | Porphyromonas gingivalis arginine-specific proteinase |
US5475097A (en) | 1993-10-21 | 1995-12-12 | University Of Georgia Research Foundation, Inc. | Lysine-specific Porphyromonas gingivalis proteinase |
AUPN627595A0 (en) * | 1995-10-30 | 1995-11-23 | University Of Melbourne, The | Diagnostics and treatments of periodontal disease |
KR100603552B1 (ko) * | 1997-12-10 | 2006-07-20 | 씨에스엘 리미티드 | 포피로모나스 긴기발리스 폴리펩티드 및 뉴클레오티드 |
AUPQ485999A0 (en) * | 1999-12-24 | 2000-02-03 | Csl Limited | P. gingivalis antigenic composition |
US20030083287A1 (en) * | 2000-11-30 | 2003-05-01 | Burgess Nicola A. | ginS |
-
2000
- 2000-04-28 AU AUPQ7182A patent/AUPQ718200A0/en not_active Abandoned
-
2001
- 2001-04-27 CA CA2750984A patent/CA2750984A1/en not_active Abandoned
- 2001-04-27 EP EP01925217.0A patent/EP1276762B1/en not_active Expired - Lifetime
- 2001-04-27 JP JP2001580954A patent/JP5209166B2/ja not_active Expired - Fee Related
- 2001-04-27 WO PCT/AU2001/000482 patent/WO2001083530A1/en active IP Right Grant
- 2001-04-27 DK DK01925217.0T patent/DK1276762T3/da active
- 2001-04-27 ES ES01925217T patent/ES2426034T3/es not_active Expired - Lifetime
- 2001-04-27 NZ NZ521797A patent/NZ521797A/en not_active IP Right Cessation
- 2001-04-27 CA CA2407603A patent/CA2407603C/en not_active Expired - Fee Related
-
2002
- 2002-10-28 US US10/283,024 patent/US7204991B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CA2750984A1 (en) | 2001-11-08 |
CA2407603A1 (en) | 2001-11-08 |
US7204991B2 (en) | 2007-04-17 |
NZ521797A (en) | 2005-07-29 |
CA2407603C (en) | 2013-06-11 |
EP1276762A1 (en) | 2003-01-22 |
ES2426034T3 (es) | 2013-10-18 |
EP1276762B1 (en) | 2013-05-29 |
EP1276762A4 (en) | 2004-07-07 |
US20030215402A1 (en) | 2003-11-20 |
WO2001083530A1 (en) | 2001-11-08 |
AUPQ718200A0 (en) | 2000-05-25 |
JP2003531634A (ja) | 2003-10-28 |
DK1276762T3 (da) | 2013-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5349448B2 (ja) | P.gingivalis抗原組成物 | |
JP5209166B2 (ja) | ポルフィロモナス・ジンジバリス(Porphyromonasgingivalis)リコンビナントタンパク質と末端切断物 | |
US6962706B1 (en) | Synthetic peptides containing protective epitopes for the treatment and prevention of periodontitis associated with porphyromonas gingivalis | |
JP4358909B2 (ja) | 歯周炎の診断および治療用のポルフィロモナス・ジンジバリス抗原 | |
AU2001252042B2 (en) | Porphyromonas gingivalis recombinant proteins and truncations | |
AU713844B2 (en) | Porphyromonas gingivalis antigens for the diagnosis and treatment of periodontitis | |
AU775228B2 (en) | P. gingivalis antigenic composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080415 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080415 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20090724 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20090724 |
|
RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20090826 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110104 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110404 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111220 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120314 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120322 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120604 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130129 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130221 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160301 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |